Literature DB >> 1354963

Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

C Cuvier1, L Roblot-Treupel, J M Millot, G Lizard, S Chevillard, M Manfait, P Couvreur, M F Poupon.   

Abstract

We have demonstrated that in vitro resistance of tumor cells to doxorubicin (Dox) can be fully circumvented by using doxorubicin-loaded nanospheres (Dox-NS), consisting of biodegradable polyisohexylcyanoacrylate polymers of 300 nm diameter and containing 2.83 mg of Dox per 31.5 mg of polymer. Five different multidrug-resistant cell lines, characterized by mdr1 amplification, were used in this study: Dox-R-MCF7, a human breast adenocarcinoma; SKVBL1, a human ovarian adenocarcinoma; K562-R, a human erythroleukemia; and two murine lines: P388-Adr-R, a monocytic leukemia of DBA2 mouse, and LR73MDR, a Chinese hamster ovarian cell line. These lines were 38.7, 210, 232, 143 and 20 times more resistant than their corresponding sensitive counterparts, respectively. Using Dox-NS, we obtained complete reversion of drug resistance in vitro, i.e. cell growth inhibition comparable with that obtained with sensitive cells exposed to free Dox. In vivo, we significantly prolonged the survival of DBA2 mice which had previously received P388-Adr-R cells by i.p. injections of Dox-NS, while free Dox injection was ineffective toward this rapidly growing tumor. (Prolongation of survival time: 115% vs 167% after Dox vs Dox-NS treatment, respectively.) Using the MCF7 cell line and its resistant variant, we studied the intracellular concentration and the cytoplasmic and nuclear distribution of Dox by laser microspectrofluorometry (LMSF). In sensitive cells, we observed a similar accumulation and distribution of Dox whatever the form of Dox delivery, i.e. whether free or carried by nanospheres. Analysis by LMSF showed that 99% of intranuclear Dox was bound to DNA after treatment with both forms of Dox. Of Dox, 81 and 83% were found in the intranuclear compartment of sensitive cells incubated with free Dox and Dox-NS, respectively. Resistant cells incubated with Dox-NS accumulated the same amount of Dox as sensitive cells incubated with free Dox or with Dox-NS. Dox, when loaded in nanospheres, bypasses the efflux mechanism responsible for multidrug resistance. LMSF analysis showed that Dox, transported and released by nanospheres, interacts with DNA identically in sensitive and resistant cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354963     DOI: 10.1016/0006-2952(92)90443-m

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  32 in total

Review 1.  Clinical developments in nanotechnology for cancer therapy.

Authors:  Jeremy D Heidel; Mark E Davis
Journal:  Pharm Res       Date:  2010-06-12       Impact factor: 4.200

2.  Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.

Authors:  Fei Ren; Ruda Chen; Ying Wang; Yabin Sun; Yaodong Jiang; Guofeng Li
Journal:  Pharm Res       Date:  2010-12-24       Impact factor: 4.200

Review 3.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

4.  Preparation of arsenic trioxide albumin microspheres and its release characteristics in vitro.

Authors:  Jie Zhou; Fuqing Zeng; Gao Xiang; Shusheng Xie; Shuli Wei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

5.  Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages.

Authors:  C E Soma; C Dubernet; G Barratt; F Nemati; M Appel; S Benita; P Couvreur
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

6.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  Nano Today       Date:  2013-06-01       Impact factor: 20.722

7.  A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution.

Authors:  Yilwoong Yi; Jae Hong Kim; Hye-Won Kang; Hun Seung Oh; Sung Wan Kim; Min Hyo Seo
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

Review 8.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro.

Authors:  L Manil; J C Davin; C Duchenne; C Kubiak; J Foidart; P Couvreur; P Mahieu
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

10.  Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.

Authors:  L Manil; P Couvreur; P Mahieu
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.